Evidence map›Paper›PMID 34016296›Full record

ArticleJournal of substance abuse treatment2021

Nicotine and cannabis vaping among adolescents in treatment for substance use disorders.

Kelly C Young-Wolff, Sara R Adams, Stacy A Sterling, Andy S L Tan, Ramzi G Salloum, Kira Torre, Lisa Carter-Harris, Judith J Prochaska

Open access · greenAbstract read
In one paragraph

Article in Journal of substance abuse treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Kelly C Young-WolffDivision of Research, Kaiser Permanente Northern California, USA. Electronic address: kelly.c.young-wolff@kp.org.
Sara R AdamsDivision of Research, Kaiser Permanente Northern California, USA.
Stacy A SterlingDivision of Research, Kaiser Permanente Northern California, USA.
Andy S L TanAnnenberg School for Communication, University of Pennsylvania, Philadelphia, PA, USA.
Ramzi G SalloumDepartment of Health Outcomes and Biomedical Informatics, Institute for Child Health Policy, University of Florida College of Medicine, Gainesville, FL, USA.
Kira TorreAddiction Medicine and Recovery Services, Kaiser Permanente Northern California, USA.
Lisa Carter-HarrisDepartment of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Judith J ProchaskaStanford Prevention Research Center, Department of Medicine, Stanford University, USA.
Kaiser Permanente · USMemorial Sloan Kettering Cancer Center · USStanford University · USUniversity of Florida · USUniversity of Pennsylvania · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Identifying Risk Factors for Prenatal Substance and Polysubstance UseK01DA043604 · NIDA · KAISER FOUNDATION RESEARCH INSTITUTE · PI YOUNG-WOLFF, KELLY CORINNE · 2017 to 2021
$907k
NCI NIH HHS P30 CA008748NIDA NIH HHS K01 DA043604
6 · The paper itself

Abstract

This study examined nicotine and cannabis vaping among adolescents in treatment for substance use disorders. Participants were 363 adolescents aged 12-17 (66% male, mean age = 15.5 [SD = 1.3], 46% non-Hispanic white) seen for a specialty addiction intake evaluation between 2017 and 2019 at one of six medical offices of a large, integrated health care system in Northern California. Multivariable logistic regression models tested for associations of sociodemographics, cigarette smoking, and substance use disorders with vaping behaviors. A majority of adolescents reported ever (68%) or current vaping (60%) of nicotine and/or cannabis; current vaping was similar for nicotine (50%) and cannabis (51%); 40% reported current vaping of both. Current smokers (6% of the sample) had higher odds of ever vaping (aOR = 3.95, 95%CI: 1.04-14.95). Black (versus non-Hispanic white) adolescents had lower odds of current nicotine vaping (aOR = 0.08, 95%CI: 0.02-0.37) and current vaping of both nicotine and cannabis (aOR = 0.12, 95%CI: 0.03-0.60). Having an alcohol use disorder was associated with current vaping (aOR = 2.14, 95%CI: 1.06-4.33). Those who endorsed that most friends get drunk/high (aOR = 1.87, 95%CI: 1.02-3.42) or that cannabis was their substance of choice (aOR = 2.36, 95%CI: 1.16-4.81) had higher odds of current cannabis vaping. Higher neighborhood household income ($80,000-$120,000 and >$120,000 vs. <$80,000, aORs = 2.05-9.48), never versus ever blunt use (aORs = 2.47-8.68), and intakes in 2018 and 2019 versus 2017 (aORs = 2.18-5.38) were associated with higher odds of all vaping outcomes. Vaping was common among adolescents in addiction treatment and varied with sociodemographics and substance-related factors. Research should assess how vaping impacts the development of substance use disorders and whether it interferes with addiction treatment.

Indexed as

CannabisElectronic Nicotine Delivery SystemsSubstance-Related DisordersVapingAdolescentFemaleHumansMaleNicotineNicotineAddiction treatmentAdolescentsCannabisE-cigaretteNicotineVaping

Identifiers

PMID34016296
PMCPMC8140195
OpenAlexW3125843589

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.